Health Care · Pharmaceutical Preparations

LRMR Larimar Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1374690128 filings
Russell 2000

LRMR at a glance

Larimar Therapeutics, Inc. (LRMR, SEC CIK 1374690) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Larimar Therapeutics, Inc. (LRMR) shares worth $78.4 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Clayton Russell on November 16, 2026 of 3,322 shares at $3.01 per share.
  • In the last 90 days, LRMR insiders reported 9 open-market purchases ($402K) and 0 open-market sales ($0) on Form 4, a net purchase of $402K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
9 buys · 0 sells
Net +$402K
13F holders
24 funds
$78.4M · −1 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales
  • Net loss $31.1M vs $47.7M YoY, operating loss $32.5M vs $49.5M
  • R&D expenses $25.9M vs $44.9M, G&A $6.5M vs $4.6M
  • Operating cash outflow $119.8M through nine months, cash and securities $128.7M
  • BLA submission completed November 2026, planned launch third quarter 2027 if approved, cash expected through late Q2 2027

Risk Factors

  • BLA filing risk: FDA may refuse filing or deny accelerated approval for nomlabofusp
  • Safety database risk: FDA identified adequacy as a review issue at BLA submission
  • Manufacturing compliance risk: Fill-finish manufacturer received FDA Form 483
  • Launch timing risk: Vendor remediation could delay potential approval or launch
  • Supply-chain risk: Additional fill-finish manufacturer remains under qualification

AI summary of the LRMR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter fiscal 2026 results announced for period ended September 30, 2026
  • Operational highlights included alongside financial results, with details in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Completed BLA submission for nomlabofusp, seeking accelerated approval using skin FXN as a potential surrogate endpoint
  • FDA acceptance targeted early 2027, with potential U.S. approval mid-2027 and launch targeted Q3 2027
Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Preliminary liquidity of approximately $128.7 million in cash, equivalents and marketable securities as of September 30, 2026
  • Financial close and review remain ongoing, creating potential for the liquidity figure to change

Item 8.01: Other Events

  • Completed rolling BLA submission to FDA for accelerated approval of nomlabofusp in Friedreich’s ataxia
  • Regulatory milestone potentially advances nomlabofusp toward FDA review and commercialization

Item EX-99.1: Item EX-99.1

  • Completed rolling BLA submission for nomlabofusp, seeking accelerated approval for Friedreich’s ataxia
  • FDA willing to consider skin frataxin as a novel surrogate endpoint, but acceptance and approval remain uncertain

Item EX-99.2: Item EX-99.2

  • Completed rolling BLA submission in November 2026, seeking accelerated approval using skin FXN as a novel surrogate endpoint
  • FDA acceptance targeted for early 2027, with potential U.S. approval mid-2027 and launch in Q3 2027
Filed Sep 29, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • John B. Harlow appointed President and Chief Operating Officer effective September 29, 2026, adding commercial-stage biopharma leadership
  • $560,000 base salary, $35,000 signing bonus, and target annual bonus equal to 40% of salary

AI summaries of LRMR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LRMR

Don't miss the next LRMR filing

  • Alerts as it files. A push when LRMR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LRMR, by share count.
  • Ask anything. An AI agent that reads every LRMR filing and answers with sources.

LRMR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Clayton RussellBuyNov 16, 2026$3.01
SHERMAN JEFFREY WBuyNov 16, 2026$3.06
Hamilton Thomas EdwardBuyNov 12, 2026$2.67
Celano MichaelBuyNov 11, 2026$2.71
Truitt JosephBuyNov 11, 2026$2.80
BEN-MAIMON CAROLEBuyNov 11, 2026$2.77
THOMAS FRANK EBuyNov 11, 2026$2.73
Shankar GopiBuyNov 11, 2026$2.71

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$41.8M-$90.9M-$172.5M
Net Income-$36.9M-$80.6M-$165.7M
Balance Sheet
Total Assets$95.9M$200.2M$145.8M
Equity$81.7M$171.8M$78.1M
ROE-45.2%-46.9%-212.2%
Per Share
EPS$-0.84$-1.32-
Cash Flow
Operating CF-$33.5M-$70.8M-$113.2M
CapEx$164K$515K$91K

Source: XBRL data in Larimar Therapeutics, Inc. (LRMR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LRMR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LRMR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$78.4M
Q2 202625$68.3M
Q1 202626$83.8M
Q4 202524$70.7M
Q3 202525$60.8M
Q2 202524$42.8M
Q1 202520$22.1M
Q4 202416$20.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 184 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LRMR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 16, 2026--
10-QNov 16, 2026Analysis
8-KNov 16, 2026Analysis-
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
8-KNov 9, 2026Analysis-
4Oct 1, 2026--
8-KSep 29, 2026Analysis-
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
4Jul 8, 2026--
8-KJun 29, 2026Analysis-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
8-KMay 19, 2026Analysis

Related Health Care companies

All Health Care →

LRMR SEC filings: frequently asked questions

Are LRMR insiders buying or selling?

In the last 90 days, Larimar Therapeutics, Inc. (LRMR) officers, directors and 10% owners reported 9 open-market purchases worth $402,143 by 9 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold LRMR stock?

As of September 30, 2026, the largest Larimar Therapeutics, Inc. (LRMR) holders among the 13F filers tracked by SignalX were BlackRock ($18.4 million), Vanguard Capital Management LLC ($9.5 million), Goldman Sachs Group ($9.5 million), AQR Capital Management ($7.2 million), Bank of America Corp ($6.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did LRMR report in its latest 8-K?

Larimar Therapeutics, Inc. (LRMR) filed an 8-K on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter fiscal 2026 results announced for period ended September 30, 2026.

What are the latest LRMR SEC filings?

Larimar Therapeutics, Inc. (LRMR) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 18, 2026.

What is LRMR's SEC CIK number?

Larimar Therapeutics, Inc. (LRMR)'s SEC Central Index Key (CIK) is 1374690. EDGAR lists every LRMR filing under that number.

Ask anything about LRMR

The research agent reads LRMR's filings, financials, insider trades and 13F holders, then answers with sources.